Anti-Leukemia Drug May Also Work Against Ovarian Cancer

An antibody therapy already in clinical trials to treat chronic lymphocytic leukemia (CLL) may also prove effective against ovarian cancer – and likely other cancers as well, report researchers at the University of California, San Diego School of Medicine in a study published in the Nov. 17 online early edition of the Proceedings of the National Academy of Sciences (PNAS).

The findings extend the anti-cancer potential of an experimental monoclonal antibody called cirmtuzumab, developed at UC San Diego Moores Cancer Center by Thomas Kipps, MD, PhD, and colleagues. Cirmtuzumab is currently in a first-in-human phase 1 clinical trial to assess its safety and efficacy in treating CLL. … Read the full story from the UC San Diego Newsroom


Dr. Thomas Kipps

Dr. Thomas Kipps

Thomas Kipps, MD, PhD, Evelyn and Edwin Tasch Chair in Cancer Research, is professor of medicine in the Division of Hematology-Oncology and deputy director of research at the UC San Diego Moores Cancer Center.

Dr. Kipps directs the multi-institutional, National Institutes of Health (NIH)-sponsored CLL Research Consortium (CRC) and UC San Diego Blood Cancer Research Fund.